Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections

AAPS PharmSciTech

Volumn 8, Issue 4, 2007, Pages

  Alam, Mohd Aftab ^a   Ahmad, Farhan Jalees ^a   Khan, Zeenat Iqbal ^a   Khar, Roop Krishen ^a   Ali, Mushir ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Acid buffering bioadhesive tablet; Bioadhesion; Bioadhesive polymers; Mixed vaginal infections; Vaginal infection

Indexed keywords

ALGINIC ACID; BICARBONATE; CANDID V; CARBOMER; CARBOXYMETHYLCELLULOSE; CITRATE SODIUM; CITRIC ACID; CLOTRIMAZOLE; CROSCARMELLOSE SODIUM; GUAR GUM; INFA V; MAGNESIUM STEARATE; METRONIDAZOLE; MICROCRYSTALLINE CELLULOSE; POLYCARBOPHIL; UNCLASSIFIED DRUG; XANTHAN; ACRYLIC ACID RESIN; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; BUFFER; EXCIPIENT; POLYCARBOPHIL CALCIUM; PROBIOTIC AGENT;

ACID BUFFERING BIOADHESIVE TABLET; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SPORE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG MIXTURE; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; EX VIVO STUDY; IN VITRO STUDY; LACTOBACILLUS ACIDOPHILUS; MIXED INFECTION; NONHUMAN; PH; SPECTROPHOTOMETRY; TABLET; TABLET FORMULATION; TABLET HARDNESS; TABLET PROPERTY; VAGINA DISCHARGE; VAGINITIS; ADHESION; ANIMAL; ARTIFICIAL MEMBRANE; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG FORMULATION; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; KINETICS; METHODOLOGY; MICROBIOLOGY; MUCOSA; PARASITOLOGY; PHARMACEUTICS; REPRODUCIBILITY; SOLUBILITY;

ACRYLIC RESINS; ADHESIVENESS; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; BUFFERS; CANDIDA ALBICANS; CARBOXYMETHYLCELLULOSE; CHEMISTRY, PHARMACEUTICAL; CITRATES; CLOTRIMAZOLE; DRUG COMBINATIONS; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LACTOBACILLUS ACIDOPHILUS; MEMBRANES, ARTIFICIAL; METRONIDAZOLE; MUCOUS MEMBRANE; PROBIOTICS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL; VAGINITIS;

EID: 37549071832     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0804096     Document Type: Article

References (13)

1. ACOG. ACOG technical bulletin:Vaginitis. Int J Gynecol & Obstet. 1996;53:271-280.
2. Sherrard J. European guidelines for the management of vaginal discharge. Int J STD AIDS. 2001;12:73-77.
3. Kukner S, Ergin T, Cicek N, Ugur M, Yesilyurt H, Gokmen O. Treatment of vaginitis. Int J Gynecol & Obstet. 1996;52:43-47.
4. Yu K, Chien YW. Vaginal delivery and absorption of drugs. In: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. vol. 16. New York, NY: Marcel Dekker Inc.; 1997: 153-185.
5. Deshpande AA, Rhodes CT, Danish M. Intravaginal drug delivery. Drug Dev Ind Pharm. 1992;18:1225-1279.
6. Ceschel GC, Maffei P, Borgia SL, Ronchi C, Rossi S. Development of a mucoadhesive dosage form for vaginal administration. Drug Dev Ind Pharm. 2001;27:541-547.
7. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci Tech Today. 2000;3:359-364.
8. Levinson RS, Thompson DJ. VagiSite bioadhesive technology. In: Rathbone MJ, Hadgraft J, Roberts MS, eds. Modified-release Drug Delivery Technology. New York, NY: Marcel Dekker, 2003:801-806.
9. Maggi L, Mastromarino P, Macchia S, et al. Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration. Eur J Pharm Biopharm. 2000; 50:389-395.
10. Owen DH, Katz DF. A vaginal fluid stimulant. Contraception. 1999;59:91-95.
11. Singh S, Garg S. Understanding analytical method validation. Pharm Times. 1999;8:15-20.
12. Setnikar I, Fantelli S. Liquefication time of rectal suppositories. J Pharm Sci. 1962;51:566-571.
13. De Paula IC, Ortega GG, Bassani VL, Petrovick PR. Development of ointment formulations prepared with Achyrocline satureioides spray dried extracts. Drug Dev Ind Pharm. 1998;24:235-241.